ZNF619

Across TCGA pan-cancer cohorts, ZNF619 RNA differs between tumor and matched normal tissue in 9 of 18 cancer types tested, making tumor–normal expression one of ZNF619’s most consistent transcriptional readouts.

The strongest signal is observed in thyroid carcinoma (THCA), where ZNF619 RNA is repressed in tumor relative to normal tissue. In most cancer types ZNF619 is over-expressed in tumor, although a few such as THCA and KIRC show the opposite, repressed pattern.

THCA, KIRC, and LIHC are the cancer types where ZNF619 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ZNF619 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
THCA	Male	II,III,IV	−0.716	<.001	10	view →
KIRC	Male	II,III,IV	−0.591	<.001	9	view →
LIHC	Male	All	+0.537	<.001	8	view →
BLCA	All	All	+0.564	.004	6	view →
STAD	All	II,III,IV	+0.540	<.001	6	view →
BRCA	All	II,III,IV	+0.259	.003	6	view →
COAD	Male	III,IV	+0.433	.007	4	view →
CHOL	All	All	+0.786	.003	2	view →
UCEC	All	All	−0.340	.030	2	view →
COAD	Female	IV	−1.065	.002	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 10 strongest of 9 lineages.

ZNF619–THCA

Open the THCA breakdown →